Background: Matrix metalloproteinase-9 (MMP-9) has a potential role in arterial plaque rupture, but its relation to risk of coronary heart disease (CHD) is uncertain. Aim: To determine whether circulating levels of serum MMP-9 are prospectively related to the risk of CHD in the general population. Methods: We measured baseline MMP-9 levels in stored serum samples of subjects in a case-control study nested within a prospective study of 5661 men followed up for 16 years for CHD events (465 cases, 1076 controls). Results: MMP-9 values were associated with cigarette smoking, and with several inflammatory and haemostatic markers, but not with age, body mass index, blood pressure or lipid measurements. Men in the top third of baseline MMP-9 levels had
Introduction
The mechanisms by which a low-grade chronic inflammatory state brings about atherosclerotic plaque development and subsequent rupture are the subject of much current interest. 1 Although circulating markers of general inflammation associated with the acute phase response, such as fibrinogen 2 and C-reactive protein (CRP), 3 are associated with risk of coronary heart disease (CHD) among healthy populations and those with prevalent disease, their roles in the biology of atherosclerosis remain uncertain. 4, 5 Matrix metalloproteinases (MMPs) are a family of zinc-containing zymogen endoproteinases, which have functions in the normal and injury-induced turnover of the extracellular matrix. 6 MMP-9 (gelatinase B, 92 kDa collagenase) degrades interstitial collagens, proteoglycan core protein, elastin and type IV collagen in the basement membrane.
It has been proposed that localized inflammation may promote production and activation of MMP-9, and bring about de-stabilizing structural changes in vulnerable atherosclerotic plaques. [8] [9] [10] [11] [12] [13] MMP-9 also potentiates the chemokine interleukin (IL)-8 and modifies the local chemokine profile, 14 and hence may promote cellular infiltration of the plaque, increasing the size of the necrotic core. These processes render the plaque susceptible to rupture due to reduced mechanical strength, and hence increase the probability of atherothrombotic ischaemia. Tissue studies have shown that active MMP-9 can be found in plaques in regions of foam cell accumulation 15 and that production of MMP-9 is higher in phenotypically unstable plaques than in stable ones. 10, 15, 16 Epidemiological studies have shown that MMP-9 levels are increased in the circulation of patients with acute coronary syndromes. 17, 18 However, there is very limited information on whether circulating MMP-9 is a risk factor for future cardiovascular events among healthy men. To our knowledge, the only prospective studies reported to date are based on cohorts with established baseline CHD. [19] [20] [21] [22] Data from these cohorts are conflicting, although the largest study to date (the Atherogene study, 19 n = 137 cases) reported significant independent associations between circulating MMP-9 levels with risk of cardiovascular disease (CVD) death or myocardial infarction (MI). In order to clarify the relationship between systemic circulating serum MMP-9 levels and incident CHD in the general population, we report here the results of a casecontrol study of healthy middle-aged British men, nested within a large prospective study (the British Regional Heart Study).
Methods
In 1978-80, 7735 males aged 40-59 were randomly selected from general practice registers in each of 24 British towns and invited to take part in the British Regional Heart Study (response rate 78%). Nurses administered questionnaires, made physical measurements including blood pressure, weight, height and body mass index (BMI), recorded an electrocardiograph (ECG) and collected non-fasting venous blood samples. In 5661 men in 18 of the study towns, serum was stored at À208C for subsequent analysis. 23 Pre-existing CHD was defined on the basis of a history of a doctor's diagnosis of CHD, a positive history of angina or possible MI on the Rose (WHO) chest pain questionnaire or an ECG consistent with definite or possible CHD. All men were monitored subsequently for all-cause mortality and for cardiovascular morbidity, with a follow-up loss of <1%. 24 Fatal CHD cases were ascertained through National Health Service Central Registers on the basis of a death certificate with ICD-9 codes 410-414. The diagnosis of non-fatal myocardial infarction was based on reports from general practitioners, supplemented by regular reviews of general practice records and diagnosed in accordance with WHO criteria. 24 A nested case-control study was established, based on all 643 CHD cases (279 CHD deaths and 364 cases of non-fatal MI) occurring between 1978 and 1996, and a total of 1278 controls (2 per case) 'frequency-matched' to cases on town of residence and age in 5-year bands was randomly selected from among men who had survived to the end of the study period free from incident coronary heart disease. Due to attrition of samples as a result of use in previous studies, [25] [26] [27] [28] [29] [30] residual serum samples were available for 465 of these cases and 1067 controls for MMP-9 measurements to be carried out in 2004-05. The baseline characteristics of subjects for whom serum samples were and were not available for the present study were not appreciably different from the original case-control study (P > 0.10 for case-control proportion, age distribution, residential town proportions and social class proportions).
Laboratory methods
P. Welsh, who was blind to the case-control status of participants, measured serum concentrations of MMP-9 using a commercially available sandwich ELISA (R& D Systems, Oxon, UK) (intra-assay CV 4.4%, inter-assay CV 10.4%). Markers of systemic inflammation, vascular adhesion molecules, and haematological variables were assayed as previously reported.
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Statistical analysis
Highly skewed variables were log-transformed where necessary. We pre-specified case-control analyses by thirds of MMP-9 values in controls. Unmatched stratified logistic regression was fitted using unconditional maximum likelihood methods (SAS version 8.1). The associations between MMP-9 and a variety of known and suspected CHD risk factors were examined using unmatched logistic regressions and analysis of covariance for categorical and continuous variables respectively; emphasis was mainly given to differences more extreme than 2.6 SD (2P > 0.01) to make allowance for multiple comparisons.
Results
Established vascular risk factors showed the expected differences between the case and control populations (Table 1) . Cases were more likely to have evidence of baseline CHD, to be current cigarette smokers, or to have diabetes. Cases also had a higher average BMI, and had a higher average systolic and diastolic blood pressure. They had higher average total cholesterol and triglyceride levels and lower high density lipoprotein cholesterol level, as well as elevated CRP levels at baseline. For MMP-9, geometric mean levels were higher among cases than controls (ageadjusted proportional difference 7%, 95% CI 1-13%; P = 0.03).
Baseline MMP-9 levels in the control population were significantly positively associated with markers of systemic inflammation (CRP, IL-6, serum amyloid A, white cell count), vascular adhesion molecules [E-and P-selectin and intracellular adhesion molecule (ICAM)-1, although not vascular cell adhesion molecule (VCAM)-1] and some haematological variables [haematocrit and fibrin D-dimer, but not tissue-plasminogen activator (t-PA) or von Willebrand factor (VWF) antigens] ( Table 2 ). There was no association with homocysteine levels. MMP-9 levels were inversely related to forced expiratory volume (FEV 1 ) and strongly related to cigarette smoking habits, as well as showing increasing trends with alcohol intake. Although it was weakly related to non-fasting glucose, MMP-9 showed no relationship to insulin and was not associated with other established vascular risk factors such as age, evidence of CHD at entry, blood pressure, BMI, physical activity or any lipid measurements (Table 2) .
In comparisons of men in the highest third vs. the lowest third of the MMP-9 control distribution, the age-adjusted odds ratio (OR) for CHD was 1.37 (95% CI 1.04-1.82) ( Table 3) . Adjustment for smoking status attenuated the result to borderline significance: OR 1.27 (0.96-1.69), although further adjustment for other cardiovascular risk factors did not attenuate the result further [OR 1.28 (0.95-1.74)]. After adjusting for CRP and IL-6 levels in the final model the association was attenuated towards the null: OR 1.13 (0.82-1.56). Only the age and town-adjusted model yielded a significant trend across thirds (P = 0.039). Exclusion of men with evidence of baseline CHD had little material effect on the odds ratios observed, although the age and town-adjusted association with CHD risk was no longer statistically significant.
Discussion
To our knowledge, this is the first report of circulating levels of MMP-9 with risk of CHD in a generally healthy population, and is the largest casecontrol study of MMP-9 associations with risk of CHD to date. MMP-9 showed a significant association with risk of CHD; men in the highest third of MMP-9 had an increase in CHD risk of about 40%. However, the association was attenuated following adjustment for cigarette smoking and for other inflammatory markers.
Findings of elevated levels of MMP-9 among current smokers (who are at increased CHD risk) are of particular interest, because they may reflect greater expression of MMP-9 in tissues including arterial plaques, thus increasing the risk of plaque rupture. Increased levels of MMP-9 expression among current smokers may suggest that MMP-9 is one possible pathophysiological link between cigarette smoke exposure and increased risk of CHD events. This speculative link would be consistent with data in animal and tissue models showing that MMP-9 is associated with and may confer plaque instability, [8] [9] [10] [11] [12] [13] 15, 16 and with at least one mouse model showing that smoking exposure raises pulmonary MMP-9 levels. 31 We have also shown that serum MMP-9 is associated not only with circulating inflammatory markers (in agreement with previous findings 19 ) but also with circulating levels of adhesion molecules ICAM-1, P-selectin and E-selectin. This association with circulating adhesion molecules may be more specific than a broad range association of MMP-9 with activated vascular endothelium, since MMP-9 shows no associations with two other potential markers of activated endothelium, VWF and t-PA, 32 or with VCAM-1. The mechanisms behind these differing associations are currently unclear.
Consistent with MMP-9's association with smoking habits, its association with CHD risk was attenuated after adjusting for smoking habit (OR 1.28, 95% CI 0.95-1.74), although not by adjustment for other conventional risk markers. This residual borderline association was further reduced after adjustment for IL-6 and CRP [OR 1.13 (0.82-1.56)]. These findings suggest that the association between MMP-9 and incident CHD in the general population is confounded by smoking habit and by markers of generalized inflammation. It therefore seems unlikely that MMP-9 would add further discrimination to CHD risk prediction models for the general population. More data in generally healthy populations are required to establish its association with CHD risk more reliably.
The present study suggests that the association between MMP-9 and incident CHD is modest; our best estimate is of an increase of about 40% in the highest third, with the upper 95% confidence effectively excluding a doubling of risk in this group. This association appears weaker than that previously reported in a cohort of patients with unstable angina [hazard risk ratio comparing extreme quartiles of MMP-9 in age and sex-adjusted model 2.66 (95% CI 1.42-4.99)]. 19 The difference between the studies could reflect the imprecision of the relative risk estimates (95% confidence intervals are relatively wide in both studies). Alternatively this could reflect a real difference, possibly because patients with unstable angina have a higher prevalence of unstable coronary artery plaques than the general population in the present study. MMP-9 may be a weaker marker of CHD event risk in a generally healthy cohort rather than those with established arterial disease due to the ability of MMP-9 to de-stabilize established plaques, [8] [9] [10] [11] [12] [13] rather than to directly stimulate atherogenesis. This possibility is in agreement with other epidemiological data showing that production of MMP-9 is higher in phenotypically unstable than stable plaques. 10, 15, 16 Other potential explanations for the difference in these reports include that the present study was performed using serum samples, whilst the Atherogene report used plasma. 19 The ELISA we used did not recommend use of plasma samples due to chelation issues for MMPs.
Although MMP-9 is unlikely to prove a clinically useful biomarker of CHD risk based on these results, an OR of 1.4 for CHD comparing extreme thirds of a general population can be described as moderate. To put these results in context, a 1 mmol/l increase in LDL total cholesterol in the general population results in a 12% increase in relative risk. 33 Therefore the potential role of MMP-9 in the aetiology of CHD in the general population should not be discounted, and its potential as a therapeutic target requires further consideration. The major strength of this study is that it is a large prospective study nested within a well-maintained cohort study with high follow-up rates. Limitations of the study include the age of the samples ($24 years at time of assay), and we cannot exclude the possibility that degradation may have had some bearing on our results. MMP-9 is known to be labile even at low temperatures of storage, and as such degradation of samples over even short epidemiological time frames is unavoidable. One study has shown that plasma MMP-9 levels fall by 65% after 2 years storage at À808C. 34 Our own analysis of 10 serum samples stored at À508C for 1 year is consistent with this, showing a 28.5% drop in median detectable levels, although the fall in levels was uniform (log-transformed Spearman correlation at 1 year vs. baseline = 0.93) (Welsh et al., unpublished observations). It is difficult to extrapolate these results to storage conditions over $24 years, and studies of MMP-9 stability over such a long period have not yet been performed to our knowledge. However, in the present study all cases and controls were treated in the same manner and, based on the limited available data, we would anticipate reasonably uniform effects of storage conditions on the samples MMP-9 levels. Our observations regarding significant MMP-9 associations with smoking habits and CRP but not with lipid measurements are consistent with the Atherogene study report of samples stored for a shorter time period, 19 and a recent cross-sectional study which also used plasma. 35 Furthermore, the long-stored samples used in the present nested casecontrol study have been used in studies of several other novel potential cardiovascular risk factors, [25] [26] [27] [28] [29] [30] including the cytokine IL-6, 30 and yielded similar results to other studies in which samples were stored for shorter periods. Finally, it may be important to note that circulating active MMP-9 could be a better marker of risk of CHD than MMP-9 antigen (both pre-MMP-9 and active MMP-9) measured here. This possibility requires further epidemiological study.
Conclusion
There is a significant association between serum MMP-9 and incident CHD in the general population. This is largely related to cigarette smoking exposure and to circulating markers of generalized inflammation. The association is of biological interest and is consistent with a potential role for MMP-9 in pathogenesis of CHD. However, MMP-9 is unlikely to be a clinically useful additional risk predictor for CHD in the general population.
